Alnylam Pharmaceuticals Discontinues Revusiran Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Morgan Stanley Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 7, 2016 6:32 AM EDTMorgan Stanley downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $36.00.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $36.21 yesterday.
... MoreAlnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
October 6, 2016 7:39 AM EDTChardan Capital Markets analyst Madhu Kumar cut the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $77.00 (from $115.00) after the company announced the discontinuation of the development of revusiran, a RNAi drug
which was in phase III trials targeting transthyretin (TTR), for the treatment of TTR familial amyloid... More
Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness
October 6, 2016 7:26 AM EDTNeedham & Company analyst Alan Carr cut his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $137.00 (from $152.00) after the company reported last night that the revusiran program has been terminated. An ad hoc review of unblinded Phase 3 ENDEAVOR trial data led the DMC... More
Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'
October 6, 2016 7:23 AM EDTCredit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained an Outperform after the company announced termination of revusiran.
Young commented, "Lowering TP to $50/sh due to concerns about broader implications to the... More
Alnylam (ALNY) PT Cut to $58 at Jefferies
October 6, 2016 6:47 AM EDTJefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.
Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of... More
JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
October 6, 2016 6:41 AM EDTJPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $51.00 (from $83.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
... MoreBarclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 6, 2016 6:41 AM EDTBarclays downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $50.00 (from $85.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
... MoreLeerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform
October 6, 2016 6:39 AM EDTLeerink Partners downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Market Perform with a price target of $40.00 (from $107.00) after the company discontinued development of revusiran.
Analyst Michael Schmidt commented, "We are downgrading ALNY to Market Perform following today's news that the company has discontinued development of... More
